recent post

University of Central Lancashire signs MoU with Brinton Healthcare for nanotechnology research

October 14, 2024
recent post

KIMSHEALTH Trivandrum opens electrophysiology lab equipped with 3D Mapping

recent post

M|O|C opens cancer centre in Tanzania

recent post

Kolkata scientists identify therapy to help cancer patients overcome resistance to current treatments

October 11, 2024
recent post

Holy Family Hospital in Bandra, Mumbai opens one-stop breast clinic

imt Logo cross btn

Dr Reddy’s Laboratories launches Difluprednate Ophthalmic Emulsion 0.05 per cent in US

Dr Reddy's Laboratories launches Difluprednate Ophthalmic Emulsion 0.05 per cent in US

Difluprednate Ophthalmic Emulsion 0.05 per cent is available in 5 ml bottles in case packs of 24 Dr Reddy's Laboratories has launched Difluprednate Ophthalmic Emulsion 0.05 per cent, a therapeutic generic equivalent to Durezol (Difluprednate Ophthalmic Emulsion 0.05 per cent) in the US market, following the approval by the US Food and Drug Administration (US FDA). The Durezol brand and generic had US sales of approximately $40 million MAT for the most recent twelve months ending in Nov 2022 according to IQVIA. Dr Reddy’s Difluprednate Ophthalmic Emulsion 0.05 per cent is available in 5 ml bottles in case packs of 24.